1
|
Eleftheriadou I, Kokkinos A, Liatis S,
Makrilakis K, Tentolouris N, Tentolouris A and Tsapogas P: Atlas of
the Diabetic Foot. 3rd edition. Wiley-Blackwell, Hoboken, NJ,
2019.
|
2
|
Jeffcoate WJ, Vileikyte L, Boyko EJ,
Armstrong DG and Boulton AJM: Current challenges and opportunities
in the prevention and management of diabetic foot ulcers. Diabetes
Care. 41:645–652. 2018.PubMed/NCBI View Article : Google Scholar
|
3
|
Tzeravini E, Tentolouris A, Tentolouris N
and Jude EB: Advancements in improving health-related quality of
life in patients living with diabetic foot ulcers. Expert Rev
Endocrinol Metab. 13:307–316. 2018.PubMed/NCBI View Article : Google Scholar
|
4
|
Armstrong DG, Boulton AJM and Bus SA:
Diabetic foot ulcers and their recurrence. N Engl J Med.
376:2367–2375. 2017.PubMed/NCBI View Article : Google Scholar
|
5
|
Tentolouris N, Edmonds ME, Jude EB, Vas
PRJ, Manu CA, Tentolouris A and Eleftheriadou I: Editorial:
Understanding diabetic foot disease: Current status and emerging
treatment approaches. Front Endocrinol (Lausanne).
12(753181)2021.PubMed/NCBI View Article : Google Scholar
|
6
|
Baltzis D, Eleftheriadou I and Veves A:
Pathogenesis and treatment of impaired wound healing in diabetes
mellitus: New insights. Adv Ther. 31:817–836. 2014.PubMed/NCBI View Article : Google Scholar
|
7
|
Schaper NC, van Netten JJ, Apelqvist J,
Bus SA, Fitridge R, Game F, Monteiro-Soares M and Senneville E:
IWGDF Editorial Board. Practical guidelines on the prevention and
management of diabetes-related foot disease (IWGDF 2023 update).
Diabetes Metab Res Rev. 40(e3657)2024.PubMed/NCBI View Article : Google Scholar
|
8
|
Tentolouris A and Tentolouris N: Methods
of ulcer healing. In: Atlas of the Diabetic Foot. Wiley-Blackwell,
Hoboken, NJ, pp205-228, 2019.
|
9
|
Eleftheriadou I, Tentolouris A,
Tentolouris N and Papanas N: Advancing pharmacotherapy for diabetic
foot ulcers. Expert Opin Pharmacother. 20:1153–1160.
2019.PubMed/NCBI View Article : Google Scholar
|
10
|
Eleftheriadou I, Samakidou G, Tentolouris
A, Papanas N and Tentolouris N: Nonpharmacological management of
diabetic foot ulcers: An update. Int J Low Extrem Wounds.
20:188–197. 2021.PubMed/NCBI View Article : Google Scholar
|
11
|
Chen P, Vilorio NC, Dhatariya K, Jeffcoate
W, Lobmann R, McIntosh C, Piaggesi A, Steinberg J, Vas P,
Viswanathan V, et al: Guidelines on interventions to enhance
healing of foot ulcers in people with diabetes (IWGDF 2023 update).
Diabetes Metab Res Rev. 40(e3644)2024.PubMed/NCBI View Article : Google Scholar
|
12
|
Burgess JL, Wyant WA, Abdo Abujamra B,
Kirsner RS and Jozic I: Diabetic wound-healing science. Medicina
(Kaunas). 57(1072)2021.PubMed/NCBI View Article : Google Scholar
|
13
|
Tentolouris A, Eleftheriadou I, Tzeravini
E, Tsilingiris D, Paschou SA, Siasos G and Tentolouris N:
Endothelium as a therapeutic target in diabetes mellitus: From
basic mechanisms to clinical practice. Curr Med Chem. 27:1089–1131.
2020.PubMed/NCBI View Article : Google Scholar
|
14
|
Prompers L, Huijberts M, Apelqvist J, Jude
E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A,
Mauricio D, et al: High prevalence of ischaemia, infection and
serious comorbidity in patients with diabetic foot disease in
Europe. Baseline results from the Eurodiale study. Diabetologia.
50:18–25. 2007.PubMed/NCBI View Article : Google Scholar
|
15
|
Crews RT, Shen BJ, Campbell L, Lamont PJ,
Boulton AJ, Peyrot M, Kirsner RS and Vileikyte L: Role and
determinants of adherence to off-loading in diabetic foot ulcer
healing: A prospective investigation. Diabetes Care. 39:1371–1377.
2016.PubMed/NCBI View Article : Google Scholar
|
16
|
Wu L, Norman G, Dumville JC, O'Meara S and
Bell-Syer SE: Dressings for treating foot ulcers in people with
diabetes: An overview of systematic reviews. Cochrane Database Syst
Rev. 2015(CD010471)2015.PubMed/NCBI View Article : Google Scholar
|
17
|
Edmonds M, Lazaro-Martinez JL,
Alfayate-Garcia JM, Martini J, Petit JM, Rayman G, Lobmann R,
Uccioli L, Sauvadet A, Bohbot S, et al: Sucrose octasulfate
dressing versus control dressing in patients with neuroischaemic
diabetic foot ulcers (Explorer): An international, multicentre,
double-blind, randomised, controlled trial. Lancet Diabetes
Endocrinol. 6:186–196. 2018.PubMed/NCBI View Article : Google Scholar
|
18
|
Wen J, Jin X, Al Sayah F, Johnson JA,
Paulden M and Ohinmaa A: Economic evaluation of sucrose octasulfate
dressing for treatment of diabetic foot ulcers in patients with
type 2 diabetes. Can J Diabetes. 46:126–133. 2022.PubMed/NCBI View Article : Google Scholar
|
19
|
Lobmann R, Augustin M, Lawall H, Tigges W,
Potempa C, Thiem H, Fietz C and Rychlik RP: Cost-effectiveness of
TLC-sucrose octasulfate versus control dressings in the treatment
of diabetic foot ulcers. J Wound Care. 28:808–816. 2019.PubMed/NCBI View Article : Google Scholar
|
20
|
Maunoury F, Oury A, Fortin S, Thomassin L,
Bohbot S and Explorer S: Cost-effectiveness of TLC-NOSF dressings
versus neutral dressings for the treatment of diabetic foot ulcers
in France. PLoS One. 16(e0245652)2021.PubMed/NCBI View Article : Google Scholar
|
21
|
Volkin DB, Verticelli AM, Marfia KE, Burke
CJ, Mach H and Middaugh CR: Sucralfate and soluble sucrose
octasulfate bind and stabilize acidic fibroblast growth factor.
Biochim Biophys Acta. 1203:18–26. 1993.PubMed/NCBI View Article : Google Scholar
|
22
|
Kulahin N, Kiselyov V, Kochoyan A,
Kristensen O, Kastrup JS, Berezin V, Bock E and Gajhede M:
Dimerization effect of sucrose octasulfate on rat FGF1. Acta
Crystallogr Sect F Struct Biol Cryst Commun. 64(Pt 6):448–452.
2008.PubMed/NCBI View Article : Google Scholar
|
23
|
Game F, Jeffcoate W, Tarnow L, Jacobsen
JL, Whitham DJ, Harrison EF, Ellender SJ, Fitzsimmons D and Löndahl
M: LeucoPatch II trial team. LeucoPatch system for the management
of hard-to-heal diabetic foot ulcers in the UK, Denmark, and
Sweden: An observer-masked, randomised controlled trial. Lancet
Diabetes Endocrinol. 6:870–878. 2018.PubMed/NCBI View Article : Google Scholar
|
24
|
Barritault D, Gilbert-Sirieix M, Rice KL,
Siñeriz F, Papy-Garcia D, Baudouin C, Desgranges P, Zakine G,
Saffar JL and van Neck J: RGTA((R)) or ReGeneraTing Agents mimic
heparan sulfate in regenerative medicine: From concept to curing
patients. Glycoconj J. 34:325–338. 2017.PubMed/NCBI View Article : Google Scholar
|
25
|
Barritault D, Desgranges P, Meddahi-Pelle
A, Denoix JM and Saffar JL: RGTA((R))-based matrix therapy-A new
branch of regenerative medicine in locomotion. Joint Bone Spine.
84:283–292. 2017.PubMed/NCBI View Article : Google Scholar
|
26
|
Tong M, Tuk B, Hekking IM, Vermeij M,
Barritault D and van Neck JW: Stimulated neovascularization,
inflammation resolution and collagen maturation in healing rat
cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic,
OTR4120. Wound Repair Regen. 17:840–852. 2009.PubMed/NCBI View Article : Google Scholar
|
27
|
Tong M, Tuk B, Shang P, Hekking IM,
Fijneman EM, Guijt M, Hovius SE and van Neck JW: Diabetes-impaired
wound healing is improved by matrix therapy with heparan sulfate
glycosaminoglycan mimetic OTR4120 in rats. Diabetes. 61:2633–2641.
2012.PubMed/NCBI View Article : Google Scholar
|
28
|
Papanas N, Demetzos C, Pippa N, Maltezos E
and Tentolouris N: Efficacy of a new heparan sulfate mimetic
dressing in the healing of foot and lower extremity ulcerations in
type 2 diabetes: A case series. Int J Low Extrem Wounds. 15:63–67.
2016.PubMed/NCBI View Article : Google Scholar
|
29
|
Samakidou G, Eleftheriadou I, Anastasiou
IA, Kosta O, Tentolouris A, Evangelou K and Tentolouris N: A single
center, randomized controlled trial on the efficacy of topical
application of regenerating tissue agents (RGTA) technology in
diabetic foot ulcers. Int J Low Extrem Wounds: Jun 4, 2024 (Epub
ahead of print).
|
30
|
Pradhan Nabzdyk L, Kuchibhotla S, Guthrie
P, Chun M, Auster ME, Nabzdyk C, Deso S, Andersen N, Gnardellis C,
LoGerfo FW and Veves A: Expression of neuropeptides and cytokines
in a rabbit model of diabetic neuroischemic wound healing. J Vasc
Surg. 58:766–775 e12. 2013.PubMed/NCBI View Article : Google Scholar
|
31
|
Huang YY, Lin CW, Cheng NC, Cazzell SM,
Chen HH, Huang KF, Tung KY, Huang HL, Lin PY, Perng CK, et al:
Effect of a novel macrophage-regulating drug on wound healing in
patients with diabetic foot ulcers: A Randomized clinical trial.
JAMA Netw Open. 4(e2122607)2021.PubMed/NCBI View Article : Google Scholar
|
32
|
Edmonds ME, Bodansky HJ, Boulton AJM,
Chadwick PJ, Dang CN, D'Costa R, Johnston A, Kennon B, Leese G,
Rajbhandari SM, et al: Multicenter, randomized controlled,
observer-blinded study of a nitric oxide generating treatment in
foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair
Regen. 26:228–237. 2018.PubMed/NCBI View Article : Google Scholar
|
33
|
Ziche M and Morbidelli L: Nitric oxide and
angiogenesis. J Neurooncol. 50:139–148. 2000.PubMed/NCBI View Article : Google Scholar
|
34
|
Guzik TJ, Korbut R and Adamek-Guzik T:
Nitric oxide and superoxide in inflammation and immune regulation.
J Physiol Pharmacol. 54:469–487. 2003.PubMed/NCBI
|
35
|
Liu J, Chen Z, Wang J, Li R, Li T, Chang
M, Yan F and Wang Y: Encapsulation of curcumin nanoparticles with
MMP9-responsive and thermos-sensitive hydrogel improves diabetic
wound healing. ACS Appl Mater Interfaces. 10:16315–16326.
2018.PubMed/NCBI View Article : Google Scholar
|
36
|
Dong Y, Rodrigues M, Kwon SH, Li X, A S,
Brett EA, Elvassore N, Wang W and Gurtner GC: Acceleration of
diabetic wound regeneration using an in situ-formed stem-cell-based
skin substitute. Adv Healthc Mater. 7(e1800432)2018.PubMed/NCBI View Article : Google Scholar
|
37
|
Ding Z, Zhang Y, Guo P, Duan T, Cheng W,
Guo Y, Zheng X, Lu G, Lu Q and Kaplan DL: Injectable
desferrioxamine-laden silk nanofiber hydrogels for accelerating
diabetic wound healing. ACS Biomater Sci Eng. 7:1147–1158.
2021.PubMed/NCBI View Article : Google Scholar
|
38
|
Chen H, Jia P, Kang H, Zhang H, Liu Y,
Yang P, Yan Y, Zuo G, Guo L, Jiang M, et al: Upregulating Hif-1α by
hydrogel nanofibrous scaffolds for rapidly recruiting angiogenesis
relative cells in diabetic wound. Adv Healthc Mater. 5:907–918.
2016.PubMed/NCBI View Article : Google Scholar
|
39
|
Duscher D, Neofytou E, Wong VW, Maan ZN,
Rennert RC, Inayathullah M, Januszyk M, Rodrigues M, Malkovskiy AV,
Whitmore AJ, et al: Transdermal deferoxamine prevents
pressure-induced diabetic ulcers. Proc Natl Acad Sci USA.
112:94–99. 2015.PubMed/NCBI View Article : Google Scholar
|
40
|
Edwards J and Stapley S: Debridement of
diabetic foot ulcers. Cochrane Database Syst Rev.
2010(CD003556)2010.PubMed/NCBI View Article : Google Scholar
|
41
|
Lebrun E, Tomic-Canic M and Kirsner RS:
The role of surgical debridement in healing of diabetic foot
ulcers. Wound Repair Regen. 18:433–438. 2010.PubMed/NCBI View Article : Google Scholar
|
42
|
Game FL and Jeffcoate WJ: Dressing and
diabetic foot ulcers: A current review of the evidence. Plast
Reconstr Surg. 138 (3 Suppl):158S–164S. 2016.PubMed/NCBI View Article : Google Scholar
|
43
|
Sherman RA: Mechanisms of maggot-induced
wound healing: what do we know, and where do we go from here? Evid
Based Complement Alternat Med. 2014(592419)2014.PubMed/NCBI View Article : Google Scholar
|
44
|
Sun XJ, Chen JA, Li G, Wang L, Wang TY and
Wang AP: Maggot debridement therapy stimulates wound healing by
altering macrophage activation. Int Wound J.
21(e14477)2024.PubMed/NCBI View Article : Google Scholar
|
45
|
Sherman RA: Maggot therapy for treating
diabetic foot ulcers unresponsive to conventional therapy. Diabetes
Care. 26:446–451. 2003.PubMed/NCBI View Article : Google Scholar
|
46
|
McPherson M, Carroll M and Stewart S:
Patient-perceived and practitioner-perceived barriers to accessing
foot care services for people with diabetes mellitus: A systematic
literature review. J Foot Ankle Res. 15(92)2022.PubMed/NCBI View Article : Google Scholar
|
47
|
Musuuza J, Sutherland BL, Kurter S,
Balasubramanian P, Bartels CM and Brennan MB: A systematic review
of multidisciplinary teams to reduce major amputations for patients
with diabetic foot ulcers. J Vasc Surg. 71:1433–1446 e3.
2020.PubMed/NCBI View Article : Google Scholar
|